<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02669940</url>
  </required_header>
  <id_info>
    <org_study_id>P15-743</org_study_id>
    <nct_id>NCT02669940</nct_id>
  </id_info>
  <brief_title>Observational, Multi-Center Study of the Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation</brief_title>
  <acronym>HCV RWE</acronym>
  <official_title>Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation - An Observational, Multi-Center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to assess the effectiveness, patient reported outcomes, work productivity
      and healthcare resource utilization of the interferon-free regimen of paritaprevir /ritonavir
      (r) - ombitasvir, ± dasabuvir ± ribavirin (RBV) in participants with chronic hepatitis C in a
      real life setting across clinical practice populations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 15, 2016</start_date>
  <completion_date type="Actual">July 4, 2017</completion_date>
  <primary_completion_date type="Actual">July 4, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-Treatment (SVR12)</measure>
    <time_frame>12 weeks after the last actual dose of study drug</time_frame>
    <description>SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) levels &lt; 50 IU/mL 12 weeks after the last actual dose of paritaprevir/r - ombitasvir, ± dasabuvir, ± RBV.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Meeting SVR12 Non-Response Categories of Breakthrough, Failure to Suppress, and/or Relapse</measure>
    <time_frame>12 weeks after last actual dose of study drug</time_frame>
    <description>Breakthrough is defined as at least 1 documented HCV RNA &lt;50 IU/mL followed by HCV RNA ≥50 IU/mL during treatment. Failure to suppress is defined as each measured on-treatment HCV RNA value ≥ 50 IU/mL. Relapse is defined as HCV RNA &lt; 50 IU/mL at end of treatment or at the last on-treatment HCV RNA measurement followed by HCV RNA ≧ 50 IU/mL posttreatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVR12 Non-Response: Percentage of Participants With Breakthrough</measure>
    <time_frame>12 weeks after the last actual dose of study drug</time_frame>
    <description>Breakthrough is defined as at least 1 documented HCV RNA &lt;50 IU/mL followed by HCV RNA ≥50 IU/mL during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVR12 Non-Response: Percentage of Participants With Failure to Suppress</measure>
    <time_frame>12 weeks after the last actual dose of study drug</time_frame>
    <description>Failure to suppress is defined as each measured on-treatment HCV RNA value ≥ 50 IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVR12 Non-Response: Percentage of Participants With Relapse</measure>
    <time_frame>12 weeks after last actual dose of study drug</time_frame>
    <description>Relapse is defined as HCV RNA &lt;50 IU/mL at EoT or at the last on-treatment HCV RNA measurement followed by HCV RNA ≧ 50 IU/mL posttreatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVR12 Non-Response: Percentage of Participants With Premature Study Drug Discontinuation With No On-Treatment Virologic Failure</measure>
    <time_frame>12 weeks after last actual dose of study drug</time_frame>
    <description>On-treatment virologic failure included virological breakthrough and failure to suppress. Virological breakthrough was defined as at least one documented HCV RNA &lt; 50 IU/mL or undetectable/negative followed by HCV RNA ≥ 50 IU/mL during treatment. Failure to suppress was defined as each measured on-treatment HCV RNA value ≥ 50 IU/mL or positive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVR12 Non-Response: Percentage of Participants With Missing SVR12 Data</measure>
    <time_frame>12 weeks after last actual dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Sustained Virologic Response 24 Weeks Post-Treatment (SVR24)</measure>
    <time_frame>24 weeks after last actual dose of study drug</time_frame>
    <description>SVR24 is defined as HCV RNA levels &lt; 50 IU/mL 24 weeks after the last actual dose of paritaprevir/r - ombitasvir, ± dasabuvir, ± RBV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Virological Response at End of Treatment</measure>
    <time_frame>From baseline until end of treatment (12 or 24 weeks after actual first dose)</time_frame>
    <description>Virologic response is defined as HCV RNA &lt; 50 IU/mL.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Participants Achieving SVR12: Additional Analysis</measure>
    <time_frame>12 weeks after the last actual dose of study drug</time_frame>
    <description>SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) levels &lt; 50 IU/mL or undetectable/negative 12 weeks after the last actual dose of paritaprevir/r - ombitasvir, ± dasabuvir, ± RBV.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants Meeting SVR12 Non-Response Categories of Breakthrough, Failure to Suppress, and/or Relapse: Additional Analysis</measure>
    <time_frame>12 weeks after last actual dose of study drug</time_frame>
    <description>Breakthrough is defined as at least 1 documented HCV RNA &lt;50 IU/mL or undetectable/negative followed by HCV RNA ≥50 IU/mL or positive during treatment. Failure to suppress is defined as each measured on-treatment HCV RNA value ≥ 50 IU/mL or positive. Relapse is defined as HCV RNA &lt; 50 IU/mL or undetectable/negative at end of treatment or at the last on-treatment HCV RNA measurement followed by HCV RNA ≧ 50 IU/mL or positive posttreatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>SVR12 Non-Response: Percentage of Participants With Breakthrough: Additional Analysis</measure>
    <time_frame>12 weeks after the last actual dose of study drug</time_frame>
    <description>Breakthrough is defined as at least 1 documented HCV RNA &lt;50 IU/mL or undetectable/negative followed by HCV RNA ≥50 IU/mL or positive during treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>SVR12 Non-Response: Percentage of Participants With Failure to Suppress: Additional Analysis</measure>
    <time_frame>12 weeks after the last actual dose of study drug</time_frame>
    <description>Failure to suppress is defined as each measured on-treatment HCV RNA value ≥ 50 IU/mL or positive.</description>
  </other_outcome>
  <other_outcome>
    <measure>SVR12 Non-Response: Percentage of Participants With Relapse: Additional Analysis</measure>
    <time_frame>12 weeks after last actual dose of study drug</time_frame>
    <description>Relapse is defined as HCV RNA &lt; 50 IU/mL or undetectable/negative at end of treatment or at the last on-treatment HCV RNA measurement followed by HCV RNA ≧ 50 IU/mL or positive posttreatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants Achieving SVR24: Additional Analysis</measure>
    <time_frame>24 weeks after last actual dose of study drug</time_frame>
    <description>SVR24 is defined as HCV RNA levels &lt; 50 IU/mL or undetectable/negative 24 weeks after the last actual dose of paritaprevir/r - ombitasvir, ± dasabuvir, ± RBV.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants Achieving Virological Response at End of Treatment: Additional Analysis</measure>
    <time_frame>From baseline until end of treatment (12 or 24 weeks after actual first dose)</time_frame>
    <description>Virologic response is defined as HCV RNA &lt; 50 IU/mL or undetectable/negative.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">158</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <condition>Genotype 1</condition>
  <arm_group>
    <arm_group_label>Participants With Chronic Hepatitis C Genotype 1</arm_group_label>
    <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir ± RBV according to standard of care and in line with the current local label.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Treatment-naïve or -experienced adult male or female patients with confirmed chronic
        hepatitis C genotype 1, receiving combination therapy with paritaprevir/r - ombitasvir with
        or without dasabuvir ± RBV according to standard of care and in line with the current local
        label.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients are eligible for observation in this cohort if the following applies:

          -  Treatment-naïve or -experienced adult male or female patients with confirmed chronic
             hepatitis C, genotype 1, receiving combination therapy with paritaprevir/r -
             ombitasvir with or without dasabuvir ± RBV according to standard of care and in line
             with the current local label

          -  If RBV is co-administered with paritaprevir/r - ombitasvir with or without dasabuvir,
             it has been prescribed in line with the current local label (with special attention to
             contraception requirements and contraindication during pregnancy)

          -  Patients must voluntarily sign and date informed consent prior to inclusion into the
             study

        Exclusion Criteria:

          -  Patient must not be participating or intending to participate in a concurrent
             interventional therapeutic trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrey Strugovschikov, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <removed_countries>
    <country>Russian Federation</country>
  </removed_countries>
  <link>
    <url>http://rxabbvie.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>January 28, 2016</study_first_submitted>
  <study_first_submitted_qc>January 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2016</study_first_posted>
  <results_first_submitted>July 2, 2018</results_first_submitted>
  <results_first_submitted_qc>October 18, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 14, 2018</results_first_posted>
  <last_update_submitted>October 18, 2018</last_update_submitted>
  <last_update_submitted_qc>October 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ombitasvir</keyword>
  <keyword>Dasabuvir</keyword>
  <keyword>Paritaprevir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 2, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT02669940/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 26, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT02669940/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir + RBV</title>
          <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/ritonavir [r] - ombitasvir with or without dasabuvir with ribavirin (RBV) according to standard of care and in line with the current local label.</description>
        </group>
        <group group_id="P2">
          <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir - RBV</title>
          <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir without RBV according to standard of care and in line with the current local label.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Failure to return</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient follow-up data</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt; 55 days (for 12-week treatment) or &gt; 139 days (for 24-week treatment).</population>
      <group_list>
        <group group_id="B1">
          <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir + RBV</title>
          <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir with RBV according to standard of care and in line with the current local label.</description>
        </group>
        <group group_id="B2">
          <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir - RBV</title>
          <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir without RBV according to standard of care and in line with the current local label.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="63"/>
            <count group_id="B2" value="93"/>
            <count group_id="B3" value="156"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.8" spread="11.38"/>
                    <measurement group_id="B2" value="46.2" spread="11.59"/>
                    <measurement group_id="B3" value="48.1" spread="11.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian/Oriental</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White/Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-Treatment (SVR12)</title>
        <description>SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) levels &lt; 50 IU/mL 12 weeks after the last actual dose of paritaprevir/r - ombitasvir, ± dasabuvir, ± RBV.</description>
        <time_frame>12 weeks after the last actual dose of study drug</time_frame>
        <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt;55 days (for 12-week treatment) or &gt;139 days (for 24-week treatment). Subgroup: excludes participants with missing SVR12 results.</population>
        <group_list>
          <group group_id="O1">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir + RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir with RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O2">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir - RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir without RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O3">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir with or without RBV according to standard of care and in line with the current local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-Treatment (SVR12)</title>
          <description>SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) levels &lt; 50 IU/mL 12 weeks after the last actual dose of paritaprevir/r - ombitasvir, ± dasabuvir, ± RBV.</description>
          <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt;55 days (for 12-week treatment) or &gt;139 days (for 24-week treatment). Subgroup: excludes participants with missing SVR12 results.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Core Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" lower_limit="12.7" upper_limit="34.5"/>
                    <measurement group_id="O2" value="16.1" lower_limit="9.3" upper_limit="25.2"/>
                    <measurement group_id="O3" value="18.6" lower_limit="12.8" upper_limit="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Core Population Subgroup</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" lower_limit="13.4" upper_limit="36.0"/>
                    <measurement group_id="O2" value="17.0" lower_limit="9.9" upper_limit="26.6"/>
                    <measurement group_id="O3" value="19.6" lower_limit="13.5" upper_limit="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Meeting SVR12 Non-Response Categories of Breakthrough, Failure to Suppress, and/or Relapse</title>
        <description>Breakthrough is defined as at least 1 documented HCV RNA &lt;50 IU/mL followed by HCV RNA ≥50 IU/mL during treatment. Failure to suppress is defined as each measured on-treatment HCV RNA value ≥ 50 IU/mL. Relapse is defined as HCV RNA &lt; 50 IU/mL at end of treatment or at the last on-treatment HCV RNA measurement followed by HCV RNA ≧ 50 IU/mL posttreatment.</description>
        <time_frame>12 weeks after last actual dose of study drug</time_frame>
        <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt; 55 days (for 12-week treatment) or &gt; 139 days (for 24-week treatment). Subgroup: excludes participants with missing SVR12 results.</population>
        <group_list>
          <group group_id="O1">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, + RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir with RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O2">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, - RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir without RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O3">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir with or without RBV according to standard of care and in line with the current local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Meeting SVR12 Non-Response Categories of Breakthrough, Failure to Suppress, and/or Relapse</title>
          <description>Breakthrough is defined as at least 1 documented HCV RNA &lt;50 IU/mL followed by HCV RNA ≥50 IU/mL during treatment. Failure to suppress is defined as each measured on-treatment HCV RNA value ≥ 50 IU/mL. Relapse is defined as HCV RNA &lt; 50 IU/mL at end of treatment or at the last on-treatment HCV RNA measurement followed by HCV RNA ≧ 50 IU/mL posttreatment.</description>
          <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt; 55 days (for 12-week treatment) or &gt; 139 days (for 24-week treatment). Subgroup: excludes participants with missing SVR12 results.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Core Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.0" lower_limit="60.3" upper_limit="83.4"/>
                    <measurement group_id="O2" value="78.5" lower_limit="68.8" upper_limit="86.3"/>
                    <measurement group_id="O3" value="76.3" lower_limit="68.8" upper_limit="82.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Core Population Subgroup</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.7" lower_limit="64.0" upper_limit="86.6"/>
                    <measurement group_id="O2" value="83.0" lower_limit="73.4" upper_limit="90.1"/>
                    <measurement group_id="O3" value="80.4" lower_limit="73.1" upper_limit="86.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SVR12 Non-Response: Percentage of Participants With Breakthrough</title>
        <description>Breakthrough is defined as at least 1 documented HCV RNA &lt;50 IU/mL followed by HCV RNA ≥50 IU/mL during treatment.</description>
        <time_frame>12 weeks after the last actual dose of study drug</time_frame>
        <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt; 55 days (for 12-week treatment) or &gt; 139 days (for 24-week treatment). Subgroup: excludes participants with missing SVR12 results.</population>
        <group_list>
          <group group_id="O1">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, + RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir with RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O2">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, - RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir without RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O3">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir with or without RBV according to standard of care and in line with the current local label.</description>
          </group>
        </group_list>
        <measure>
          <title>SVR12 Non-Response: Percentage of Participants With Breakthrough</title>
          <description>Breakthrough is defined as at least 1 documented HCV RNA &lt;50 IU/mL followed by HCV RNA ≥50 IU/mL during treatment.</description>
          <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt; 55 days (for 12-week treatment) or &gt; 139 days (for 24-week treatment). Subgroup: excludes participants with missing SVR12 results.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Core Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.0" upper_limit="8.5"/>
                    <measurement group_id="O2" value="3.2" lower_limit="0.7" upper_limit="9.1"/>
                    <measurement group_id="O3" value="2.6" lower_limit="0.7" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Core Population Subgroup</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.0" upper_limit="8.9"/>
                    <measurement group_id="O2" value="3.4" lower_limit="0.7" upper_limit="9.6"/>
                    <measurement group_id="O3" value="2.7" lower_limit="0.7" upper_limit="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SVR12 Non-Response: Percentage of Participants With Failure to Suppress</title>
        <description>Failure to suppress is defined as each measured on-treatment HCV RNA value ≥ 50 IU/mL.</description>
        <time_frame>12 weeks after the last actual dose of study drug</time_frame>
        <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt; 55 days (for 12-week treatment) or &gt; 139 days (for 24-week treatment). Subgroup: excludes participants with missing SVR12 results.</population>
        <group_list>
          <group group_id="O1">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, + RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir) with RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O2">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, - RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir without RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O3">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir) with or without RBV according to standard of care and in line with the current local label.</description>
          </group>
        </group_list>
        <measure>
          <title>SVR12 Non-Response: Percentage of Participants With Failure to Suppress</title>
          <description>Failure to suppress is defined as each measured on-treatment HCV RNA value ≥ 50 IU/mL.</description>
          <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt; 55 days (for 12-week treatment) or &gt; 139 days (for 24-week treatment). Subgroup: excludes participants with missing SVR12 results.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Core Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.9" lower_limit="48.8" upper_limit="73.9"/>
                    <measurement group_id="O2" value="54.8" lower_limit="44.2" upper_limit="65.2"/>
                    <measurement group_id="O3" value="57.7" lower_limit="49.5" upper_limit="65.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Core Population Subgroup</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.0" lower_limit="51.6" upper_limit="76.9"/>
                    <measurement group_id="O2" value="58.0" lower_limit="47.0" upper_limit="68.4"/>
                    <measurement group_id="O3" value="60.8" lower_limit="52.5" upper_limit="68.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SVR12 Non-Response: Percentage of Participants With Relapse</title>
        <description>Relapse is defined as HCV RNA &lt;50 IU/mL at EoT or at the last on-treatment HCV RNA measurement followed by HCV RNA ≧ 50 IU/mL posttreatment.</description>
        <time_frame>12 weeks after last actual dose of study drug</time_frame>
        <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt; 55 days (for 12-week treatment) or &gt; 139 days (for 24-week treatment). Subgroup: excludes participants with missing SVR12 results.</population>
        <group_list>
          <group group_id="O1">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, + RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir with RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O2">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, - RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir without RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O3">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir with or without RBV according to standard of care and in line with the current local label.</description>
          </group>
        </group_list>
        <measure>
          <title>SVR12 Non-Response: Percentage of Participants With Relapse</title>
          <description>Relapse is defined as HCV RNA &lt;50 IU/mL at EoT or at the last on-treatment HCV RNA measurement followed by HCV RNA ≧ 50 IU/mL posttreatment.</description>
          <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt; 55 days (for 12-week treatment) or &gt; 139 days (for 24-week treatment). Subgroup: excludes participants with missing SVR12 results.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Core Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="3.6" upper_limit="19.6"/>
                    <measurement group_id="O2" value="20.4" lower_limit="12.8" upper_limit="30.1"/>
                    <measurement group_id="O3" value="16.0" lower_limit="10.6" upper_limit="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Core Population Subgroup</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="3.8" upper_limit="20.5"/>
                    <measurement group_id="O2" value="21.6" lower_limit="13.5" upper_limit="31.6"/>
                    <measurement group_id="O3" value="16.9" lower_limit="11.2" upper_limit="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SVR12 Non-Response: Percentage of Participants With Premature Study Drug Discontinuation With No On-Treatment Virologic Failure</title>
        <description>On-treatment virologic failure included virological breakthrough and failure to suppress. Virological breakthrough was defined as at least one documented HCV RNA &lt; 50 IU/mL or undetectable/negative followed by HCV RNA ≥ 50 IU/mL during treatment. Failure to suppress was defined as each measured on-treatment HCV RNA value ≥ 50 IU/mL or positive.</description>
        <time_frame>12 weeks after last actual dose of study drug</time_frame>
        <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt; 55 days (for 12-week treatment) or &gt; 139 days (for 24-week treatment). Subgroup: excludes participants with missing SVR12 results.</population>
        <group_list>
          <group group_id="O1">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, + RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir) with RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O2">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, - RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir) without RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O3">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir with or without RBV according to standard of care and in line with the current local label.</description>
          </group>
        </group_list>
        <measure>
          <title>SVR12 Non-Response: Percentage of Participants With Premature Study Drug Discontinuation With No On-Treatment Virologic Failure</title>
          <description>On-treatment virologic failure included virological breakthrough and failure to suppress. Virological breakthrough was defined as at least one documented HCV RNA &lt; 50 IU/mL or undetectable/negative followed by HCV RNA ≥ 50 IU/mL during treatment. Failure to suppress was defined as each measured on-treatment HCV RNA value ≥ 50 IU/mL or positive.</description>
          <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt; 55 days (for 12-week treatment) or &gt; 139 days (for 24-week treatment). Subgroup: excludes participants with missing SVR12 results.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Core Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="5.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="3.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Core Population Subgroup</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="4.1"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SVR12 Non-Response: Percentage of Participants With Missing SVR12 Data</title>
        <time_frame>12 weeks after last actual dose of study drug</time_frame>
        <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt; 55 days (for 12-week treatment) or &gt; 139 days (for 24-week treatment).</population>
        <group_list>
          <group group_id="O1">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, + RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir) with RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O2">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, - RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir without RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O3">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir with or without RBV according to standard of care and in line with the current local label.</description>
          </group>
        </group_list>
        <measure>
          <title>SVR12 Non-Response: Percentage of Participants With Missing SVR12 Data</title>
          <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt; 55 days (for 12-week treatment) or &gt; 139 days (for 24-week treatment).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="1.0" upper_limit="13.3"/>
                    <measurement group_id="O2" value="5.4" lower_limit="1.8" upper_limit="12.1"/>
                    <measurement group_id="O3" value="5.1" lower_limit="2.2" upper_limit="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Sustained Virologic Response 24 Weeks Post-Treatment (SVR24)</title>
        <description>SVR24 is defined as HCV RNA levels &lt; 50 IU/mL 24 weeks after the last actual dose of paritaprevir/r - ombitasvir, ± dasabuvir, ± RBV.</description>
        <time_frame>24 weeks after last actual dose of study drug</time_frame>
        <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt; 55 days (for 12-week treatment) or &gt; 139 days (for 24-week treatment). Subgroup: excludes participants with missing SVR12 results.</population>
        <group_list>
          <group group_id="O1">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, + RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir with RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O2">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, - RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir without RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O3">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir with or without RBV according to standard of care and in line with the current local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Sustained Virologic Response 24 Weeks Post-Treatment (SVR24)</title>
          <description>SVR24 is defined as HCV RNA levels &lt; 50 IU/mL 24 weeks after the last actual dose of paritaprevir/r - ombitasvir, ± dasabuvir, ± RBV.</description>
          <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt; 55 days (for 12-week treatment) or &gt; 139 days (for 24-week treatment). Subgroup: excludes participants with missing SVR12 results.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Core Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6" lower_limit="11.5" upper_limit="32.7"/>
                    <measurement group_id="O2" value="14.0" lower_limit="7.7" upper_limit="22.7"/>
                    <measurement group_id="O3" value="16.7" lower_limit="11.2" upper_limit="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Core Population Subgroup</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="10.8" upper_limit="32.3"/>
                    <measurement group_id="O2" value="13.6" lower_limit="7.2" upper_limit="22.6"/>
                    <measurement group_id="O3" value="16.2" lower_limit="10.7" upper_limit="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Virological Response at End of Treatment</title>
        <description>Virologic response is defined as HCV RNA &lt; 50 IU/mL.</description>
        <time_frame>From baseline until end of treatment (12 or 24 weeks after actual first dose)</time_frame>
        <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt; 55 days (for 12-week treatment) or &gt; 139 days (for 24-week treatment). Subgroup: excludes participants with missing SVR12 results.</population>
        <group_list>
          <group group_id="O1">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, + RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir with RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O2">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, - RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir without RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O3">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir with or without RBV according to standard of care and in line with the current local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Virological Response at End of Treatment</title>
          <description>Virologic response is defined as HCV RNA &lt; 50 IU/mL.</description>
          <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt; 55 days (for 12-week treatment) or &gt; 139 days (for 24-week treatment). Subgroup: excludes participants with missing SVR12 results.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Core Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.7" lower_limit="20.6" upper_limit="44.7"/>
                    <measurement group_id="O2" value="30.1" lower_limit="21.0" upper_limit="40.5"/>
                    <measurement group_id="O3" value="30.8" lower_limit="23.6" upper_limit="38.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Core Population Subgroup</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.7" lower_limit="20.3" upper_limit="45.0"/>
                    <measurement group_id="O2" value="30.7" lower_limit="21.3" upper_limit="41.4"/>
                    <measurement group_id="O3" value="31.1" lower_limit="23.7" upper_limit="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Achieving SVR12: Additional Analysis</title>
        <description>SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) levels &lt; 50 IU/mL or undetectable/negative 12 weeks after the last actual dose of paritaprevir/r - ombitasvir, ± dasabuvir, ± RBV.</description>
        <time_frame>12 weeks after the last actual dose of study drug</time_frame>
        <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt;55 days (for 12-week treatment) or &gt;139 days (for 24-week treatment). Subgroup: excludes participants with missing SVR12 results.</population>
        <group_list>
          <group group_id="O1">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir + RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir with RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O2">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir - RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir without RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O3">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir with or without RBV according to standard of care and in line with the current local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving SVR12: Additional Analysis</title>
          <description>SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) levels &lt; 50 IU/mL or undetectable/negative 12 weeks after the last actual dose of paritaprevir/r - ombitasvir, ± dasabuvir, ± RBV.</description>
          <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt;55 days (for 12-week treatment) or &gt;139 days (for 24-week treatment). Subgroup: excludes participants with missing SVR12 results.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Core Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.7" lower_limit="84.5" upper_limit="98.2"/>
                    <measurement group_id="O2" value="93.5" lower_limit="86.5" upper_limit="97.6"/>
                    <measurement group_id="O3" value="93.6" lower_limit="88.5" upper_limit="96.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Core Population Subgroup</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3" lower_limit="91.1" upper_limit="100"/>
                    <measurement group_id="O2" value="98.9" lower_limit="93.8" upper_limit="100"/>
                    <measurement group_id="O3" value="98.6" lower_limit="95.2" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Meeting SVR12 Non-Response Categories of Breakthrough, Failure to Suppress, and/or Relapse: Additional Analysis</title>
        <description>Breakthrough is defined as at least 1 documented HCV RNA &lt;50 IU/mL or undetectable/negative followed by HCV RNA ≥50 IU/mL or positive during treatment. Failure to suppress is defined as each measured on-treatment HCV RNA value ≥ 50 IU/mL or positive. Relapse is defined as HCV RNA &lt; 50 IU/mL or undetectable/negative at end of treatment or at the last on-treatment HCV RNA measurement followed by HCV RNA ≧ 50 IU/mL or positive posttreatment.</description>
        <time_frame>12 weeks after last actual dose of study drug</time_frame>
        <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt; 55 days (for 12-week treatment) or &gt; 139 days (for 24-week treatment). Subgroup: excludes participants with missing SVR12 results.</population>
        <group_list>
          <group group_id="O1">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, + RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir with RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O2">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, - RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir without RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O3">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir with or without RBV according to standard of care and in line with the current local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Meeting SVR12 Non-Response Categories of Breakthrough, Failure to Suppress, and/or Relapse: Additional Analysis</title>
          <description>Breakthrough is defined as at least 1 documented HCV RNA &lt;50 IU/mL or undetectable/negative followed by HCV RNA ≥50 IU/mL or positive during treatment. Failure to suppress is defined as each measured on-treatment HCV RNA value ≥ 50 IU/mL or positive. Relapse is defined as HCV RNA &lt; 50 IU/mL or undetectable/negative at end of treatment or at the last on-treatment HCV RNA measurement followed by HCV RNA ≧ 50 IU/mL or positive posttreatment.</description>
          <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt; 55 days (for 12-week treatment) or &gt; 139 days (for 24-week treatment). Subgroup: excludes participants with missing SVR12 results.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Core Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.0" upper_limit="8.5"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.0" upper_limit="5.8"/>
                    <measurement group_id="O3" value="1.3" lower_limit="0.2" upper_limit="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Core Population Subgroup</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.0" upper_limit="8.9"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O3" value="1.4" lower_limit="0.2" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>SVR12 Non-Response: Percentage of Participants With Breakthrough: Additional Analysis</title>
        <description>Breakthrough is defined as at least 1 documented HCV RNA &lt;50 IU/mL or undetectable/negative followed by HCV RNA ≥50 IU/mL or positive during treatment.</description>
        <time_frame>12 weeks after the last actual dose of study drug</time_frame>
        <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt; 55 days (for 12-week treatment) or &gt; 139 days (for 24-week treatment). Subgroup: excludes participants with missing SVR12 results.</population>
        <group_list>
          <group group_id="O1">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, + RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir with RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O2">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, - RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir without RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O3">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir with or without RBV according to standard of care and in line with the current local label.</description>
          </group>
        </group_list>
        <measure>
          <title>SVR12 Non-Response: Percentage of Participants With Breakthrough: Additional Analysis</title>
          <description>Breakthrough is defined as at least 1 documented HCV RNA &lt;50 IU/mL or undetectable/negative followed by HCV RNA ≥50 IU/mL or positive during treatment.</description>
          <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt; 55 days (for 12-week treatment) or &gt; 139 days (for 24-week treatment). Subgroup: excludes participants with missing SVR12 results.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Core Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="5.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="3.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Core Population Subgroup</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="4.1"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>SVR12 Non-Response: Percentage of Participants With Failure to Suppress: Additional Analysis</title>
        <description>Failure to suppress is defined as each measured on-treatment HCV RNA value ≥ 50 IU/mL or positive.</description>
        <time_frame>12 weeks after the last actual dose of study drug</time_frame>
        <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt; 55 days (for 12-week treatment) or &gt; 139 days (for 24-week treatment). Subgroup: excludes participants with missing SVR12 results.</population>
        <group_list>
          <group group_id="O1">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, + RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir) with RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O2">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, - RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir without RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O3">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir) with or without RBV according to standard of care and in line with the current local label.</description>
          </group>
        </group_list>
        <measure>
          <title>SVR12 Non-Response: Percentage of Participants With Failure to Suppress: Additional Analysis</title>
          <description>Failure to suppress is defined as each measured on-treatment HCV RNA value ≥ 50 IU/mL or positive.</description>
          <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt; 55 days (for 12-week treatment) or &gt; 139 days (for 24-week treatment). Subgroup: excludes participants with missing SVR12 results.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Core Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.0" upper_limit="8.5"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="3.9"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.0" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Core Population Subgroup</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.0" upper_limit="8.9"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="4.1"/>
                    <measurement group_id="O3" value="0.7" lower_limit="0.0" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>SVR12 Non-Response: Percentage of Participants With Relapse: Additional Analysis</title>
        <description>Relapse is defined as HCV RNA &lt; 50 IU/mL or undetectable/negative at end of treatment or at the last on-treatment HCV RNA measurement followed by HCV RNA ≧ 50 IU/mL or positive posttreatment.</description>
        <time_frame>12 weeks after last actual dose of study drug</time_frame>
        <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt; 55 days (for 12-week treatment) or &gt; 139 days (for 24-week treatment). Subgroup: excludes participants with missing SVR12 results.</population>
        <group_list>
          <group group_id="O1">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, + RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir with RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O2">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, - RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir without RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O3">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir with or without RBV according to standard of care and in line with the current local label.</description>
          </group>
        </group_list>
        <measure>
          <title>SVR12 Non-Response: Percentage of Participants With Relapse: Additional Analysis</title>
          <description>Relapse is defined as HCV RNA &lt; 50 IU/mL or undetectable/negative at end of treatment or at the last on-treatment HCV RNA measurement followed by HCV RNA ≧ 50 IU/mL or positive posttreatment.</description>
          <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt; 55 days (for 12-week treatment) or &gt; 139 days (for 24-week treatment). Subgroup: excludes participants with missing SVR12 results.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Core Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="5.7"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.0" upper_limit="5.8"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.0" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Core Population Subgroup</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.0" upper_limit="6.2"/>
                    <measurement group_id="O3" value="0.7" lower_limit="0.0" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Achieving SVR24: Additional Analysis</title>
        <description>SVR24 is defined as HCV RNA levels &lt; 50 IU/mL or undetectable/negative 24 weeks after the last actual dose of paritaprevir/r - ombitasvir, ± dasabuvir, ± RBV.</description>
        <time_frame>24 weeks after last actual dose of study drug</time_frame>
        <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt; 55 days (for 12-week treatment) or &gt; 139 days (for 24-week treatment). Subgroup: excludes participants with missing SVR12 results.</population>
        <group_list>
          <group group_id="O1">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, + RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir with RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O2">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, - RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir without RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O3">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir with or without RBV according to standard of care and in line with the current local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving SVR24: Additional Analysis</title>
          <description>SVR24 is defined as HCV RNA levels &lt; 50 IU/mL or undetectable/negative 24 weeks after the last actual dose of paritaprevir/r - ombitasvir, ± dasabuvir, ± RBV.</description>
          <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt; 55 days (for 12-week treatment) or &gt; 139 days (for 24-week treatment). Subgroup: excludes participants with missing SVR12 results.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Core Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.7" lower_limit="84.5" upper_limit="98.2"/>
                    <measurement group_id="O2" value="92.5" lower_limit="85.1" upper_limit="96.9"/>
                    <measurement group_id="O3" value="92.9" lower_limit="87.7" upper_limit="96.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Core Population Subgroup</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.0" lower_limit="86.1" upper_limit="99.0"/>
                    <measurement group_id="O2" value="95.5" lower_limit="88.8" upper_limit="98.7"/>
                    <measurement group_id="O3" value="95.3" lower_limit="90.5" upper_limit="98.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Achieving Virological Response at End of Treatment: Additional Analysis</title>
        <description>Virologic response is defined as HCV RNA &lt; 50 IU/mL or undetectable/negative.</description>
        <time_frame>From baseline until end of treatment (12 or 24 weeks after actual first dose)</time_frame>
        <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt; 55 days (for 12-week treatment) or &gt; 139 days (for 24-week treatment). Subgroup: excludes participants with missing SVR12 results.</population>
        <group_list>
          <group group_id="O1">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, + RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir with RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O2">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, - RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir without RBV according to standard of care and in line with the current local label.</description>
          </group>
          <group group_id="O3">
            <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± RBV</title>
            <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir with or without RBV according to standard of care and in line with the current local label.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Virological Response at End of Treatment: Additional Analysis</title>
          <description>Virologic response is defined as HCV RNA &lt; 50 IU/mL or undetectable/negative.</description>
          <population>Core population: eligible, enrolled participants with known fibrosis status who started the treatment combination recommended in the current local label for their disease characteristics, and remained on treatment for &gt; 55 days (for 12-week treatment) or &gt; 139 days (for 24-week treatment). Subgroup: excludes participants with missing SVR12 results.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Core Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.7" lower_limit="84.5" upper_limit="98.2"/>
                    <measurement group_id="O2" value="95.7" lower_limit="89.4" upper_limit="98.8"/>
                    <measurement group_id="O3" value="94.9" lower_limit="90.1" upper_limit="97.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Core Population Subgroup</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.0" lower_limit="86.1" upper_limit="99.0"/>
                    <measurement group_id="O2" value="96.6" lower_limit="90.4" upper_limit="99.3"/>
                    <measurement group_id="O3" value="95.9" lower_limit="91.4" upper_limit="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The observational period for participants receiving 12 weeks of paritaprevir/r - ombitasvir, ± dasabuvir, ± RBV was maximum 36 weeks (12 weeks treatment and 24 weeks posttreatment observation). For participants receiving 24 weeks of paritaprevir/r - ombitasvir, ± dasabuvir, ± RBV the observational period was maximum 48 weeks (24 weeks treatment and 24 weeks posttreatment observation).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, + RBV</title>
          <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir with RBV according to standard of care and in line with the current local label.</description>
        </group>
        <group group_id="E2">
          <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, - RBV</title>
          <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir without RBV according to standard of care and in line with the current local label.</description>
        </group>
        <group group_id="E3">
          <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± RBV</title>
          <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir with or without RBV according to standard of care and in line with the current local label.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Axillary vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie</organization>
      <phone>800-633-9110</phone>
      <email>abbvieclinicaltrials@abbvie.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

